907 related articles for article (PubMed ID: 17692726)
21. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
[TBL] [Abstract][Full Text] [Related]
22. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
Moro-Alvarez MJ; Díaz-Curiel M
Clin Interv Aging; 2008; 3(2):227-32. PubMed ID: 18686745
[TBL] [Abstract][Full Text] [Related]
23. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
Epstein S
Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
[TBL] [Abstract][Full Text] [Related]
24. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
Cramer JA; Silverman S
Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
[TBL] [Abstract][Full Text] [Related]
25. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Gold DT; Safi W; Trinh H
Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
27. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
28. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.
Migliore A; Broccoli S; Massafra U; Cassol M; Frediani B
Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):658-67. PubMed ID: 23543450
[TBL] [Abstract][Full Text] [Related]
29. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Rietbrock S; Olson M; van Staa TP
QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
[TBL] [Abstract][Full Text] [Related]
33. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD
Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
[TBL] [Abstract][Full Text] [Related]
34. Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis.
Dempster DW; Bolognese MA
J Clin Densitom; 2006; 9(1):58-65. PubMed ID: 16731432
[TBL] [Abstract][Full Text] [Related]
35. Adherence, patient preference and dosing frequency: understanding the relationship.
Reginster JY; Rabenda V; Neuprez A
Bone; 2006 Apr; 38(4 Suppl 1):S2-6. PubMed ID: 16520104
[TBL] [Abstract][Full Text] [Related]
36. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
[TBL] [Abstract][Full Text] [Related]
37. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
38. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
Kendler D; Kung AW; Fuleihan Gel-H; González González JG; Gaines KA; Verbruggen N; Melton ME
Maturitas; 2004 Jul; 48(3):243-51. PubMed ID: 15207890
[TBL] [Abstract][Full Text] [Related]
39. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
Racewicz AJ; Schofield PJ; Cahall DL; Cline GA; Burgio DE
Curr Med Res Opin; 2007 Dec; 23(12):3079-89. PubMed ID: 17971285
[TBL] [Abstract][Full Text] [Related]
40. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis.
Jones TJ; Petrella RJ; Crilly R
J Rheumatol; 2008 Sep; 35(9):1865-73. PubMed ID: 18709688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]